<DOC>
	<DOC>NCT00624364</DOC>
	<brief_summary>This trial is conducted in Africa. The aim of this trial is to evaluate the efficacy and safety of biphasic insulin aspart plus OAD compared to biphasic insulin aspart alone on blood glucose control in type 2 diabetes.</brief_summary>
	<brief_title>Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Type 2 diabetes Currently treated with maximum doses of any kind of OAD alone or any kind of oral combination therapy for at least 2 months Body mass index (BMI) below 40.0 kg/m2 HbA1c between 7.513.0% History of drug or alcohol dependence Mental incapacity, unwillingness or language barriers precluding adequate Subjects previously screened to participation or having already participated in this trial Receipt of any investigational drug within the last month prior to this trial Known or suspected allergy to trial products or related products</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>